3 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Berlin Cures GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID BC 007 or matching placebo - Long Covid | Phase 2 | Completed | Berlin Cures GmbH | 119 | 2023-06-16 | 2024-11-18 |
| The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor BC 007 - Cardiomyopathy, Dilated, Heart Failure | Phase 2 | Completed | Berlin Cures GmbH | 30 | 2019-03-29 | 2023-04-03 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects BC 007, NaCl 0.9 % - Healthy Volunteers | Phase 1 | Completed | Berlin Cures GmbH | 74 | 2016-08-01 | 2018-07-18 |
Heart Failure (2) · Cardiomyopathies (1) · Cardiomyopathy, Dilated (1) · Familial Primary Pulmonary Hypertension (1) · Fatigue Syndrome, Chronic (1) · Post-Acute COVID-19 Syndrome (1)
Sodium Chloride (1)
Germany (2) · Austria (1) · Finland (1) · Serbia (1) · Spain (1) · Switzerland (1)
Angela Sinn, Dr. (1) · Axel Mescheder, Dr. (1)
2015 (1)